



Substitute for form 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/559,148
Filing Date	August 17, 2006
First Named Inventor	Jane Louise HOLLEY
Art Unit	
Examiner Name	
Attorney Docket Number	41577/323890

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/K.M./		Behr, et al., 'Anti-Carcinoembryonic antigen Antibodies versus Somatostatin Analogs in the Detection of Metastatic Medullary Thyroid Carcinoma,' <i>Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer</i> , Supplement to <i>Cancer</i> , pp. 2436-2457 (1997)	
		Hibbs, et al., 'Experience with the Use of an Investigational F(ab') ₂ Heptavalent Botulism Immune Globulin of Equine Origin During an Outbreak an Outbreak of Type E Botulism in Egypt,' <i>Clinical Infectious Diseases</i> , 23:337-340 (1996)	
		Ismail, et al., 'Pharmacokinetics of ¹²⁵ I-Labelled IgG, F(ab') ₂ and Fab Fractions of Scorpion and Snake Antivenins: Merits and Potential for Therapeutic Use,' <i>Toxicon</i> , 36(11):1523-1528 (1998)	
		Mayers, et al., 'Anti-immunoglobulin Responses to IgG, F(ab') ₂ , and Fab Botulinum Antitoxins in Mice,' <i>Immunopharmacology and Immunotoxicology</i> , 25(3):397-408 (2003)	
		Mayers, et al., 'Antitoxin therapy for botulinum intoxication,' <i>Reviews in Medical Microbiology</i> , 12(1):29-37 (2001)	
		Muller, et al., 'Phage-displayed and soluble mouse scFv fragments neutralize rabies virus,' <i>Journal of Virological Methods</i> , 67:221-233 (1997)	
		Steele, et al., 'Further Evidence for Cross-Linking as a Protective Factor in Experimental Cholera: Properties of Antibody Fragments,' <i>The Journal of Infectious Diseases</i> , 132(2):175-180 (1975)	
		Vassilev, et al., 'Protective Activity of Two Human Intravenous Immunoglobulin Preparations in Experimental Infection with an Encapsulated Staphylococcus Aureus Strain,' <i>Acta Microbiologica Hungarica</i> , 34(2):139-145 (1987)	
↓		Vaz, et al., 'Higher protective activity of Fab' fragment compared to F(ab') ₂ and IgG on experimental tetanus,' <i>Mircen Journal of Appl. Microbiol. & Biotech.</i> , 4(3):339-348 (1988)	

Examiner
Signature

/Kerima Maasho/

Date
Considered

08/27/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.